Jacobs Levy Equity Management’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
Other funds holding MCRB
LPC
Jacobs Levy Equity Management's MCRB Position: Q3 2026 in Review
Jacobs Levy Equity Management opened a new position in Seres Therapeutics (MCRB) in Q3 2026: 134,375 shares worth $450K. The stake represents ﹤0.01% of the portfolio and ranks #786 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in MCRB as recently as Q4 2023.
Jacobs Levy Equity Management first reported a position in MCRB in Q4 2017 and has held it in 17 quarters since. The position peaked at $10.7M in Q4 2021. 40 funds tracked by Wall St. Rank hold MCRB as of Q3 2026.
- Jacobs Levy Equity Management held 134,375 shares of Seres Therapeutics worth $450K as of Q3 2026.
- Seres Therapeutics was a new Jacobs Levy Equity Management position in Q3 2026.
- Seres Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q3 2026, its #786 holding.
- Jacobs Levy Equity Management first reported a position in Seres Therapeutics in Q4 2017 and has held it in 17 quarters since.
- Jacobs Levy Equity Management's Seres Therapeutics position peaked at $10.7M in Q4 2021.
- 40 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2026, filed 16 Nov 2026.